[Skip to Content]
[Skip to Content Landing]
November 18, 2009

Simplifying the Approach to the Management of Dyslipidemia

Author Affiliations

Author Affiliations: Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, Massachusetts (Dr J. M. Gaziano); Divisions of Cardiology (Drs J. M. Gaziano and T. A. Gaziano), Aging (Dr J. M. Gaziano), and Preventive Medicine (Dr J. M. Gaziano), Department of Medicine, Brigham and Women's Hospital, Boston; and Center for Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston (Dr T. A. Gaziano). Dr J. M. Gaziano is also Contributing Editor, JAMA.

JAMA. 2009;302(19):2148-2149. doi:10.1001/jama.2009.1685

In this issue of JAMA, Kuklina and colleagues1 report trends over the last decade in cholesterol levels and treatment. While the decreasing prevalence of “high” low-density lipoprotein cholesterol (LDL-C) levels and increasing use of lipid-lowering medications in appropriate individuals are encouraging, the most sobering message in this article is the disappointing rates of screening, awareness, and treatment. Among those with high LDL-C levels, one-third had not been screened, and one-fourth were unaware that their levels were high. About two-thirds of those who were high risk were not receiving medication, although the vast majority of these individuals would likely benefit from lipid-lowering therapy.